RFA FOR COLORECTAL LIVER METASTASES
THE EORTC CLOCC TRIAL AND WHAT IT MEANS

Colorectal cancer is one of the most common cancers globally, and the liver is the dominant site of metastatic spread — approximately 50% of CRC patients develop liver metastases. The clinical management question that CLOCC was designed to answer is one of the most common in GI oncology.

“Before CLOCC, chemotherapy was the only evidence-based option for unresectable CRC liver metastases. CLOCC asked: can we do better? Can adding RFA — destroying the metastases we can see — improve survival beyond what chemotherapy alone achieves? The answer mattered for hundreds of thousands of patients.”

• The Unresectable Majority

  Only 15–20% of patients with CRC liver metastases are resectable at presentation. The remaining 80–85% have metastases that are too numerous, too bilaterally distributed, or involving critical structures such that surgical resection would leave insufficient remaining liver. For this unresectable majority, standard of care before CLOCC was chemotherapy alone — with median OS of approximately 18–24 months in FOLFOX-era series.

• The Hypothesis CLOCC Tested

  The CLOCC trial tested whether adding local ablation (RFA) to systemic chemotherapy could improve outcomes beyond chemotherapy alone. The hypothesis: chemotherapy addresses microscopic and distant disease; RFA addresses the visible liver deposits; together they might produce better disease control and longer survival than either alone.

The CLOCC trial (Chemotherapy + Local Ablation vs Chemotherapy alone for Colorectal Cancer liver metastases) is a phase III multicentre RCT conducted by the EORTC (European Organisation for Research and Treatment of Cancer).

• Trial Design and Eligibility

  Phase III open-label RCT. 119 patients with unresectable CRC liver metastases — ≤9 liver lesions (up to 3 lesions ablatable in a single RFA session), maximum lesion size 4 cm, no extrahepatic disease. Patients randomised 1:1 to (1) systemic chemotherapy alone (FOLFOX ± bevacizumab) or (2) RFA (ablation of all liver lesions) followed by the same chemotherapy regimen.

• Primary Endpoint: Progression-Free Survival

  Median PFS: RFA + chemo 16.8 months vs chemo alone 9.9 months — hazard ratio 0.570 (95% CI 0.37–0.88), p=0.010. The primary endpoint was statistically significantly met. This established that adding RFA to chemotherapy delayed disease progression by approximately 7 months compared to chemotherapy alone.

• Overall Survival (Updated 2017 Analysis)

  8-year median follow-up analysis (Ruers et al. JNCI 2017): median OS 45.6 months (RFA + chemo) vs 40.5 months (chemo alone) — hazard ratio 0.58 (95% CI 0.38–0.88), p=0.01. At the 8-year update, a statistically significant OS benefit was demonstrated. 8-year OS: 35.9% (RFA + chemo) vs 8.9% (chemo alone) — a striking long-term survival difference in selected patients.

• Key Subgroup: Single vs Multiple Lesions

  Exploratory subgroup analyses showed the benefit was most pronounced in patients with fewer and smaller lesions — reinforcing the patient selection message. Patients with 1–3 small lesions had the greatest absolute benefit from adding RFA. The CLOCC data supports the principle of "aggressive local therapy for limited liver-only disease."

Key efficacy outcomes from the CLOCC trial initial publication (2012) and 8-year update (2017).

The CLOCC eligibility criteria define the patient population most likely to benefit. Patient selection is the most important variable in translating the trial evidence to individual clinical decisions.

• The Ideal Candidate

  The CLOCC ideal patient profile: liver-only CRC metastases (no extrahepatic disease or minimal stable extrahepatic disease). Three or fewer liver lesions (1–3 is optimal). Each lesion ≤4 cm. Good performance status (ECOG 0–1). Prior chemotherapy either naive or limited. Liver function adequate for ablation (no significant cirrhosis). This profile describes patients where local control of liver disease meaningfully determines overall prognosis.

• Situations Where Benefit Is Less Clear

  Extensive extrahepatic disease — where liver control is not the limiting factor in survival. Very high-volume liver disease (>5 lesions) — where RFA cannot address all deposits. Lesions >5 cm — complete ablation rates decline, local recurrence is higher. Progressive disease on current chemotherapy — systemic disease control is the priority before adding local therapy.

CLOCC used FOLFOX ± bevacizumab — the standard regimen of the mid-2000s. Current systemic therapy is more potent. The principle extends to modern regimens.

• Modern Regimens: FOLFOXIRI + Bevacizumab

  Current first-line intensive chemotherapy for fit CRC patients (FOLFOXIRI + bevacizumab) achieves higher liver-only disease control rates than FOLFOX. Combining such regimens with RFA for residual liver lesions that respond but remain incompletely controlled represents the current evolution of the CLOCC principle — though formal RCT evidence with modern regimens is still accumulating.

• Conversion to Resectability

  For patients initially deemed unresectable, effective systemic therapy may downsize liver metastases to a point where surgical resection or ablation becomes feasible — "conversion therapy." The decision between resection and ablation for converted lesions follows the same principles as primary resectability assessment: lesions ≤3 cm are good ablation candidates; larger lesions may be better resected.

• Access to RFA + Chemotherapy: Where China and India Fit

  The CLOCC strategy — RFA for limited liver-only CRC mets combined with chemotherapy — is routinely implemented at tier-1 interventional oncology centres in China and India at substantially lower cost than Western institutions. Chinese centres with high CRC liver met volumes (reflecting China's rising CRC incidence) have particular experience with this approach.

Related RFA topics and resources.

Frequently Asked Questions

Common questions about RFA for CRC liver metastases.